MedTrace Logo

Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation

NCT02631499 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2015-12-22

No results posted yet for this study

Summary

This study is designed to prospectively evaluate whether post-hepatectomy adjuvant transcatheter arterial chemoembolization (TACE) is effective in reducing early recurrence in HCC patients with preoperative CTC ≥2.

Conditions

  • Carcinoma, Hepatocellular
  • Neoplastic Cells, Circulating

Interventions

PROCEDURE

TACE

TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.

DRUG

Epirubicin

Epirubicin is a chemotherapy drug used in TACE

DRUG

lipiodol

lipiodol is a kind of embolization material used in TACE

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Johnson & Johnson Medical, China

    collaborator INDUSTRY

  • Fudan University

    lead OTHER

Principal Investigators

  • Jia Fan, MD & PhD · Shanghai Zhongshan Hospital, Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02631499 on ClinicalTrials.gov